Scalper1 News
Gene-testing company Myriad Genetics (MYGN) will report fiscal Q4 earnings after the close Tuesday that Wall Street expects will show tougher year-over-year comparisons for the high-rated stock. Analysts’ consensus calls for 8% sales growth to $187.7 million, the slowest pace since late 2010. Profit is expected to shrink 13% to 46 cents a share. A year ago, Myriad was riding high on what observers dubbed “the Angelina Jolie effect,” after the Scalper1 News
Scalper1 News